Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of epirubicin plus
cyclophosphamide versus docetaxel plus cyclophosphamide in lymph node negative, estrogen
receptor (ER) positive, human epithelial growth factor receptor 2 (HER2) negative breast
cancer patients as adjuvant chemotherapy.